Table 2

Medication use during the trial and posttrial follow-up in the glargine study

RandomizationEnd of trialEnd of posttrial follow-up
GlargineControlP valueGlargineControlP valueGlargineControlP value
No. of participants*6,2646,2735,2675,2601,8731,887
Glucose-lowering drugs
 None2,527 (40)2,577 (41)0.40375 (7.1)1,013 (19)<0.001386 (21)449 (24)0.019
 One drug3,732 (60)3,689 (59)0.382,017 (38)2,056 (39)0.40691 (37)718 (38)0.46
  Insulin only**001,520 (29)98 (1.9)<0.001303 (16)83 (4.4)<0.001
  Other monotherapy3,732 (60)3,689 (59)0.38497 (9.4)1,958 (37)<0.001388 (21)635 (34)<0.001
 Two or more drugs5 (0.1)7 (0.1)0.572,875 (55)2,191 (42)<0.001796 (42)720 (38)0.007
  Combination with insulin**0 (0)0 (0)2,725 (52)473 (9.0)<0.001605 (32)203 (11)<0.001
  Combination without insulin5 (0.08)7 (0.11)0.57150 (2.9)1,718 (33)<0.001191 (10)517 (27)<0.001
 Basal insulin0 (0)0 (0)4,259 (81)610 (12)<0.001957 (51)286 (15)<0.001
  Insulin glargine004,225 (80)52 (1.0)<0.001772 (41)94 (5.0)<0.001
  Other basal insulin0019 (0.4)451 (8.6)<0.001185 (9.9)192 (10)0.75
 Bolus insulin00103 (2.0)265 (5.0)<0.00199 (5.3)94 (5.0)0.68
 Metformin1,694 (27)1,741 (28)0.372,451 (47)3,142 (60)<0.001969 (52)1,089 (58)<0.001
 Sulfonylurea1,901 (30)1,810 (29)0.0671,295 (25)2,446 (47)<0.001351 (19)646 (34)<0.001
 DPP-4 inhibitor or GLP-1 analog004 (0.08)18 (0.34)0.003174 (9.3)256 (14)<0.001
 Other glucose-lowering drug173 (2.8)178 (2.8)0.76195 (3.7)614 (12)<0.00155 (2.9)92 (4.9)0.002
Other cardiovascular drugs
 ACE inhibitor or ARB4,330 (69)4,351 (69)0.823,932 (77)3,926 (76)0.711,461 (78)1,438 (76)0.22
 Other antihypertension drug4,478 (72)4,518 (72)0.543,918 (76)3,916 (76)0.781,532 (82)1,514 (80)0.26
 Statin3,373 (54)3,367 (54)0.823,179 (62)3,096 (60)0.0581,353 (72)1,346 (72)0.59
 Antiplatelet4,296 (69)4,370 (70)0.213,644 (71)3,630 (71)0.571,424 (76)1,394 (74)0.15
 Omega-3 fatty acid002,386 (45)2,404 (46)0.67201 (11)181 (9.6)0.25
  • Data are n (%). ARB, angiotensin receptor blocker; DPP-4, dipeptidyl peptidase 4.

  • *Total number of consenting participants providing any medication history at each stage. Denominators for percentages in subsequent rows may be smaller.

  • **Any basal or bolus or combination or premixed insulin.